Methamphetamine Use Disorder
Research Study
Researchers are looking for adults with Methamphetamine Use Disorder to participate in a 12-week research study.
Fast Facts
Methamphetamine Use Disorder
18-65 Years Old
Reimbursement Provided
Dallas, TX
New York, NY
Greenville, SC
Albuquerque, NM
Study Background
We’re looking for ways to help people stop or reduce their meth use.
This study is seeking participants with moderate to severe methamphetamine use disorder (MUD) who are interested in reducing or stopping methamphetamine use. We want to know whether the use of the experimental drug, ketamine, is safe and effective at helping people reduce or stop using methamphetamine.
What is involved?
- Participants will be involved in the study for about 12 weeks, including 6 weeks using an experimental drug and 6 weeks of follow-up visits.
- Participants will attend about 30 study visits and 8 of these visits include infusions with the experimental study drug.
- Participants will receive either intravenous ketamine or midazolam over 8 separate visits, scheduled within a 6-week period.
- Participants will also have Cognitive Behavioral Therapy sessions once per week throughout the 12-week study duration.
We hope that eventually, the findings of this study might be useful for treating methamphetamine use disorder and improving the lives of individuals like you.
Study Background
We’re looking for ways to help people stop or reduce their meth use.
This study is seeking participants with moderate to severe methamphetamine use disorder (MUD) who are interested in reducing or stopping methamphetamine use. We want to know whether the use of the experimental drug, ketamine, is safe and effective at helping people reduce or stop using methamphetamine.
What is involved?
- Participants will be involved in the study for about 12 weeks, including 6 weeks using an experimental drug and 6 weeks of follow-up visits.
- Participants will attend about 30 study visits and 8 of these visits include infusions with the experimental study drug.
- Participants will receive either intravenous ketamine or midazolam over 8 separate visits, scheduled within a 6-week period.
- Participants will also have Cognitive Behavioral Therapy sessions once per week throughout the 12-week study duration.
We hope that eventually, the findings of this study might be useful for treating methamphetamine use disorder and improving the lives of individuals like you.
Additional Information
The purpose of the study is to determine the safety, efficacy, and feasibility of ketamine as a possible treatment for methamphetamine use disorder.
You may qualify for a study if you meet the following criteria.
- 18-65 years old
- Regular methamphetamine use
- Interested in reducing or stopping methamphetamine use
Participation lasts 12 weeks and includes about 30 study visits. All visits are approximately 6 hours long.
Active Medication Intervention (6 weeks)
- Participants will receive eight infusions over a six-week period. You may receive either ketamine or midazolam (a placebo), so that we have something with which to compare the effect of ketamine. Neither you nor the study doctors will know which one you are getting.
- 2 infusions per week during Weeks 1 to 3
- 1 infusion during Week 4
- 1 infusion during Week 6
- Participants will attend two study visits per week. They will also have Cognitive Behavioral Therapy (CBT) sessions once per week.
- Participants will need to have a ride to and from the infusions. If a ride is unavailable, the site can arrange travel for these study visits.
- Other procedures include:
- Psychiatric and medical screen
- EEG and EKG
- Blood sample collections
Follow-Up Visits (6 weeks)
- Participants will continue to attend two study visits per week
- Participants will continue to have 1 CBT session per week
Yes, participants will be reimbursed for their time.
There is no cost for you to participate in our research study.
What does KMD stand for?
KMD is an abbreviation we use to refer to this research study. KMD stands for Ketamine in Methamphetamine Use Disorder.
Is ketamine the only medication used in this research study?
No. Ketamine is the medication that we are testing as a possible treatment for methamphetamine use disorder. This research study uses another medication called midazolam as an active placebo. An active placebo is an active medication that mimics the action of the medication being tested.
What does it take to become part of the KMD research study?
We will first review the informed consent form with you to make sure you completely understand what you can expect throughout the study and so that you completely understand what is expected of you throughout the study. You will be able to decide if participating in the study is the right thing for you. If you want to participate, you will sign the informed consent form. After you sign the informed consent form, we will conduct a process called Screening to make sure the study is a good fit for you and that it is safe for you to participate.
Should I try to stop using methamphetamine now?
This study will examine if ketamine helps to reduce or stop methamphetamine use. We will not ask you to change your methamphetamine use before deciding to participate or before you start the medication. If study staff determine that you are not in a state of mind to take part in a visit as scheduled, you may be asked to reschedule.